Predictive value of ERCC1 and KRAS in colorectal cancer patients with FOLFOX chemotherapy.

被引：0
|
作者：
Lee, In Kyu
Choi, Sung-Bong
Cheung, DaeYoung
Kim, Jin Il
机构：
[1] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[2] Catholic Univ Korea, Yeouido St Marys Hosp, Seoul, South Korea
[3] Catholic Univ Korea, Coll Med, Seoul, South Korea
[4] Catholic Univ Korea, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
588
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PREDICTIVE VALUE OF KRAS MUTATION & ERCC1 OVEREXPRESSION IN COLORECTAL CANCER PATIENTS WITH FOLFOX CHEMOTHERAPY.
    Choi, S.
    Kang, W.
    Won, D.
    Lee, I.
    DISEASES OF THE COLON & RECTUM, 2016, 59 (05) : E218 - E219
  • [2] Expression of ERCC1 and TYMS in colorectal cancer patients and the predictive value of chemotherapy efficacy
    Jiang, Hong
    Li, Baosong
    Wang, Fengxia
    Ma, Chong
    Hao, Tao
    ONCOLOGY LETTERS, 2019, 18 (02) : 1157 - 1162
  • [3] Predictive value of KRAS mutation and excision repair cross-complementing 1 (ERCC1) protein overexpression in patients with colorectal cancer administered FOLFOX regimen
    Park, Sun Min
    Choi, Sung Bong
    Lee, Yoon Suk
    Lee, In Kyu
    ASIAN JOURNAL OF SURGERY, 2021, 44 (05) : 715 - 722
  • [4] Predictive Value of ERCC1, ERCC2, and XRCC1 Overexpression for Stage III Colorectal Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy
    Huang, Ming-Yii
    Tsai, Hsiang-Lin
    Lin, Chih-Hung
    Huang, Ching-Wen
    Ma, Cheng-Jen
    Huang, Chun-Ming
    Chai, Chee-Yin
    Wang, Jaw-Yuan
    JOURNAL OF SURGICAL ONCOLOGY, 2013, 108 (07) : 457 - 464
  • [5] ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
    Kim, Chee Young
    Seo, Sang Hyuk
    An, Min Sung
    Kim, Kwang Hee
    Bae, Ki Beom
    Hwang, Jin Won
    Kim, Ji Hyun
    Kim, Bo Mi
    Kang, Mi Seon
    Oh, Min Kyung
    Hong, Kwan Hee
    ANNALS OF COLOPROCTOLOGY, 2015, 31 (03) : 92 - 97
  • [6] ERCC1 and MGMT Methylation as a Predictive Marker of Relapse and FOLFOX Response in Colorectal Cancer Patients from South Tunisia
    Jamai, Dhouha
    Gargouri, Raja
    Selmi, Boulbaba
    Khabir, Abdelmajid
    GENES, 2023, 14 (07)
  • [7] ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt
    Kassem, Amira B.
    Salem, Salem Eid
    Abdelrahim, Mohamed E.
    Said, Amira S. A.
    Salahuddin, Ahmad
    Hussein, Marwa Mahmoud
    Bahnassy, Abeer A.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2017, 102 (01) : 78 - 85
  • [8] ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese
    Chai, Haina
    Pan, Jie
    Zhang, Xuelin
    Zhang, Xiaoyan
    Shen, Xiaoying
    Li, Hang
    Zhang, Kehao
    Yang, Changqing
    Sheng, Haihui
    Gao, Hengjun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2012, 5 (02): : 186 - 194
  • [9] IMPACT OF KRAS MUTATION & ERCC1 OVER-EXPRESSION ON OXALIPLATIN-BASED CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER PATIENTS.
    Park, S.
    Lee, I.
    DISEASES OF THE COLON & RECTUM, 2017, 60 (06) : E342 - E342
  • [10] Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients
    Zhang, Liping
    Zhao, Jiangman
    Yu, Bin
    Song, Xinjiang
    Sun, Guogang
    Han, Lijiang
    Wang, Lu
    Dong, Shu
    CANCER GENETICS, 2017, 218 : 51 - 57
12345